Stefano Cordio

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Giuseppe Colucci, Vittorio Gebbia, G Paoletti et al. · Journal of Clinical Oncology · 2005 · 775 citations

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

C. Aschele, L. Cionini, Sara Lonardi et al. · Journal of Clinical Oncology · 2011 · 762 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Michele Reni, Stefano Cordio, Carlo Milandri et al. · The Lancet Oncology · 2005 · 274 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8

Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial

C. Aschele, Carmine Pinto, Stefano Cordio et al. · Journal of Clinical Oncology · 2009 · 106 citations

Surgical Oncology, Cancer Management, Pathology +17